Genomma Lab Internacional traded at 17.53 this Friday February 20th, increasing 0.13 or 0.75 percent since the previous trading session. Looking back, over the last four weeks, Genomma Lab Internacional gained 0.23 percent. Over the last 12 months, its price fell by 35.53 percent. Looking ahead, we forecast Genomma Lab Internacional to be priced at 17.05 by the end of this quarter and at 15.69 in one year, according to Trading Economics global macro models projections and analysts expectations.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.